$XERS insider trading
Over the last 12 months, Xeris Biopharma Holdings insiders reported no purchases and 31 sales totaling $5.4M across SEC Form 4 filings. 97% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $5.4M 31 events
- Events · 12m
- 31 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 97% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Pieper StevenSee Remarks · O | ▼ Sale | 5,000 | $9.41 | $47K | -0.4% | plan |
| Oct 1, 2026 | McCulloch KevinSee Remarks · O | ▼ Sale | 15,000 | $9.41 | $141K | -0.9% | plan |
| Oct 1, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,666 | $9.41 | $157K | -1.5% | plan |
| Sep 28, 2026 | McCulloch KevinSee Remarks · O | ▼ Sale | 25,000 | $10 | $250K | -1.5% | plan |
| Sep 1, 2026 | McCulloch KevinSee Remarks · O | ▼ Sale | 15,000 | $8.49 | $127K | -0.9% | plan |
| Sep 1, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,666 | $8.49 | $141K | -1.5% | plan |
| Sep 1, 2026 | Pieper StevenSee Remarks · O | ▼ Sale | 5,000 | $8.5 | $43K | -0.4% | plan |
| Aug 12, 2026 | Pieper StevenSee Remarks · O | ▼ Sale | 5,000 | $8.5 | $43K | -0.4% | plan |
| Aug 3, 2026 | McCulloch KevinSee Remarks · O | ▼ Sale | 15,000 | $8.02 | $120K | -0.9% | plan |
| Aug 3, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,666 | $8.01 | $134K | -1.4% | plan |
| Jul 7, 2026 | Pieper StevenSee Remarks · O | ▼ Sale | 45,000 | $8.52 | $383K | -3.2% | plan · 2 tranches |
| Jul 1, 2026 | McCulloch KevinSee Remarks · O | ▼ Sale | 90,000 | $8.03 | $723K | -5.1% | plan |
| Jul 1, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,666 | $8.03 | $134K | -1.4% | plan |
| Jun 4, 2026 | HALKUFF DAWND | ▼ Sale | 20,000 | $6.09 | $122K | -17.4% | plan |
| Jun 4, 2026 | BORMANN-KENNEDY BARBARA-JEAN ANNED | ▼ Sale | 16,000 | $6.09 | $98K | -11.2% | plan |
| Jun 4, 2026 | JOHNSON JOHND | ▼ Sale | 15,000 | $6.09 | $91K | -2.1% | plan |
| Jun 3, 2026 | PERSKY MARLAD | ▼ Sale | 15,500 | $5.9 | $91K | -10.9% | plan |
| Jun 1, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $6.06 | $101K | -1.4% | plan |
| May 1, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $6.23 | $104K | -1.4% | plan |
| Apr 1, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $5.99 | $100K | -1.4% | plan |
| Mar 30, 2026 | Brady James AloysiusD | ▼ Sale | 10,834 | $5.54 | $60K | -10.8% | plan |
| Mar 2, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $6.25 | $104K | -1.3% | plan · 2 tranches |
| Feb 2, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $7.45 | $124K | -1.3% | plan |
| Jan 8, 2026 | McCulloch KevinSee Remarks · O | ▼ Sale | 15,000 | $8 | $120K | -0.9% | plan |
| Jan 5, 2026 | Shannon John Patrick JrSee Remarks · O·D | ▼ Sale | 24,907 | $7.08 | $176K | -0.9% | plan |
| Jan 2, 2026 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $7.43 | $124K | -1.3% | plan |
| Dec 19, 2025 | JOHNSON JOHND | ▼ Sale | 135,400 | $7.22 | $977K | -16.2% | — |
| Dec 12, 2025 | BORMANN-KENNEDY BARBARA-JEAN ANNED | ▼ Sale | 15,000 | $7.09 | $106K | -9.5% | plan |
| Dec 1, 2025 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $7.01 | $117K | -1.2% | plan |
| Nov 13, 2025 | Shannon John Patrick JrSee Remarks · O·D | ▼ Sale | 23,242 | $7.46 | $173K | -0.9% | plan |
| Nov 11, 2025 | Hecht BethSee Remarks · O | ▼ Sale | 16,667 | $7.4 | $123K | -1.2% | plan |
| Sep 11, 2025 | PERSKY MARLAD | ▼ Sale | 15,500 | $7.72 | $120K | -9.8% | plan |
| Aug 28, 2025 | SHERMAN JEFFREY WD | ▼ Sale | 42,232 | $7.92 | $335K | -16.2% | — |
| Aug 13, 2025 | JOHNSON JOHND | ▼ Sale | 107,500 | $7.32 | $786K | -11.4% | — |
| Aug 12, 2025 | HALKUFF DAWND | ▼ Sale | 42,500 | $7.28 | $309K | -27% | — |
Every $XERS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Xeris Biopharma Holdings filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $XERS feed.